MA42148A - Utilisation de prg4 pour améliorer l'acuité visuelle dynamique et les aberrations d'ordre supérieur - Google Patents

Utilisation de prg4 pour améliorer l'acuité visuelle dynamique et les aberrations d'ordre supérieur

Info

Publication number
MA42148A
MA42148A MA042148A MA42148A MA42148A MA 42148 A MA42148 A MA 42148A MA 042148 A MA042148 A MA 042148A MA 42148 A MA42148 A MA 42148A MA 42148 A MA42148 A MA 42148A
Authority
MA
Morocco
Prior art keywords
prg4
higher order
visual acuity
order aberrations
dynamic visual
Prior art date
Application number
MA042148A
Other languages
English (en)
French (fr)
Inventor
Benjamin D Sullivan
Edward R Truitt
Original Assignee
Lubris Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lubris Llc filed Critical Lubris Llc
Publication of MA42148A publication Critical patent/MA42148A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Prostheses (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyrane Compounds (AREA)
MA042148A 2015-05-19 2016-05-19 Utilisation de prg4 pour améliorer l'acuité visuelle dynamique et les aberrations d'ordre supérieur MA42148A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562163753P 2015-05-19 2015-05-19

Publications (1)

Publication Number Publication Date
MA42148A true MA42148A (fr) 2018-04-04

Family

ID=57320651

Family Applications (1)

Application Number Title Priority Date Filing Date
MA042148A MA42148A (fr) 2015-05-19 2016-05-19 Utilisation de prg4 pour améliorer l'acuité visuelle dynamique et les aberrations d'ordre supérieur

Country Status (14)

Country Link
US (1) US11666529B2 (enExample)
EP (1) EP3300482B1 (enExample)
JP (2) JP7291459B2 (enExample)
CY (1) CY1124538T1 (enExample)
DK (1) DK3300482T3 (enExample)
ES (1) ES2893304T3 (enExample)
HR (1) HRP20211589T1 (enExample)
HU (1) HUE056409T2 (enExample)
LT (1) LT3300482T (enExample)
MA (1) MA42148A (enExample)
PL (1) PL3300482T3 (enExample)
PT (1) PT3300482T (enExample)
SI (1) SI3300482T1 (enExample)
WO (1) WO2016187414A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9982027B2 (en) 2013-10-22 2018-05-29 Lubris Llc Control of rheological properties of mixed hyaluronate/lubricin solutions
EP3250221B1 (en) 2015-01-26 2020-05-27 Lubris, Llc Use of prg4 as an anti-inflammatory agent
WO2019246522A1 (en) * 2018-06-21 2019-12-26 Lubris Llc Lubricin for use in wound healing
CN113905753A (zh) * 2019-01-15 2022-01-07 康奈尔大学 重组粘蛋白和组合物以及其使用方法
JP2023515504A (ja) * 2020-02-24 2023-04-13 ノバルティス アーゲー 組み換え産生されたポリペプチドの精製

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6433142B1 (en) 1989-08-08 2002-08-13 Genetics Institute, Llc Megakaryocyte stimulating factors
US6960562B2 (en) 1999-04-23 2005-11-01 Rhode Island Hospital, A Lifespan Partner Tribonectin polypeptides and uses thereof
US7001881B1 (en) 1999-04-23 2006-02-21 Rhode Island Hospital Tribonectins
US6743774B1 (en) 1999-04-23 2004-06-01 Rhode Island Hospital Tribonectins
US7415381B2 (en) 2003-01-09 2008-08-19 Rhode Island Hospital, A Lifespan Partner Joint friction sensing
WO2005000331A2 (en) 2003-06-04 2005-01-06 Mucosal Therapeutics, Inc. Compositions for the treatment and prevention of degenerative joint disorders
WO2005102363A2 (en) 2004-04-20 2005-11-03 Mucosal Therapeutics Llc Methods of promoting cartilage healing or cartilage integration
WO2006012492A2 (en) 2004-07-23 2006-02-02 Mucosal Therapeutics Llc Compositions and methods for viscosupplementation
WO2006060473A2 (en) 2004-12-03 2006-06-08 Mucosal Therapeutics Llc Methods of treatment of injured or diseased joints with lubricin compositions
US20070111327A1 (en) 2005-05-05 2007-05-17 Jay Gregory D Methods of detecting lubricin
US8144631B2 (en) 2006-12-13 2012-03-27 Cisco Technology, Inc. Interconnecting IP video endpoints with reduced H.320 call setup time
WO2008143816A1 (en) 2007-05-15 2008-11-27 Mucosal Therapeutics Compositions and methods for reducing friction between the surface of tendons or other soft tissues
US20090068247A1 (en) 2007-09-12 2009-03-12 Mucosal Therapeutics Biocompatible devices coated with a tribonectin and methods for their production
US20090104148A1 (en) 2007-09-18 2009-04-23 Jay Gregory D Treatment and prevention of joint disease
US8506944B2 (en) * 2008-05-07 2013-08-13 The Regents Of The University Of California Replenishment and enrichment of ocular surface lubrication
EP2285364B1 (en) 2008-05-07 2015-01-21 The Regents of The University of California Therapeutic replenishment and enrichment of ocular surface lubrication
WO2010083239A2 (en) 2009-01-13 2010-07-22 Truitt Edward R Iii Therapeutic modulation of vaginal epithelium boundary lubrication
JP2012527485A (ja) 2009-05-22 2012-11-08 ルブリス，エルエルシー． Ｐｒｇ４及びその治療調節作用の応用及び使用
WO2011019963A2 (en) 2009-08-13 2011-02-17 Singularis, Inc. Prg4 treatment for interstitial cystitis
WO2011091000A2 (en) 2010-01-19 2011-07-28 Singularis, Inc. Oral care compositions and methods
KR101413390B1 (ko) 2010-07-30 2014-06-27 노파르티스 아게 수분이 풍부한 표면을 갖는 실리콘 히드로겔 렌즈
US9974685B2 (en) 2011-08-29 2018-05-22 Mati Therapeutics Drug delivery system and methods of treating open angle glaucoma and ocular hypertension
US20130116186A1 (en) 2011-10-04 2013-05-09 Rhode Island Hospital, A Lifespan Partner Lubricin injections to maintain cartilage health
US9982027B2 (en) 2013-10-22 2018-05-29 Lubris Llc Control of rheological properties of mixed hyaluronate/lubricin solutions
US10500250B2 (en) 2013-11-26 2019-12-10 Lubris Llc Compositions and methods for inhibiting intercellular interactions
US20180161393A1 (en) 2015-01-26 2018-06-14 Lubris Llc Prg4 for treating gout and its symptoms
EP3250221B1 (en) 2015-01-26 2020-05-27 Lubris, Llc Use of prg4 as an anti-inflammatory agent
US20170312335A1 (en) 2015-12-30 2017-11-02 Lubris Llc Topical use of prg4 for treatment of allergy and symptoms of inflammation

Also Published As

Publication number Publication date
JP2021167318A (ja) 2021-10-21
US11666529B2 (en) 2023-06-06
EP3300482A4 (en) 2019-02-13
EP3300482B1 (en) 2021-07-14
JP7291459B2 (ja) 2023-06-15
SI3300482T1 (sl) 2021-11-30
HUE056409T2 (hu) 2022-02-28
WO2016187414A1 (en) 2016-11-24
US20180140546A1 (en) 2018-05-24
PT3300482T (pt) 2021-10-15
CY1124538T1 (el) 2022-07-22
ES2893304T3 (es) 2022-02-08
JP2018515534A (ja) 2018-06-14
EP3300482A1 (en) 2018-04-04
DK3300482T3 (da) 2021-10-18
HRP20211589T1 (hr) 2022-01-07
LT3300482T (lt) 2021-10-25
PL3300482T3 (pl) 2022-01-03

Similar Documents

Publication Publication Date Title
EP3360032A4 (en) INTEGRATION OF CONTENTS IN NON-BROWSER APPLICATIONS
MA44955A (fr) Anticorps anti-tau et leurs méthodes d'utilisation
EP3353328A4 (en) MODULATORS OF KRAS EXPRESSION
MA43387A (fr) Anticorps anti-gitr et leurs méthodes d'utilisation
MA41028A (fr) Méthodes et formulations pour le traitement de pathologies oculaires vasculaires
EP3265113A4 (en) ANTI-LRB ANTIBODIES AND THEIR USE FOR THE DETECTION AND TREATMENT OF CANCER
EP3319611A4 (en) OXYSTEROLS AND METHOD OF USE THEREOF
MA40008A (fr) Antagoniste actrii pour le traitement et la prevention d'un ulcere cutane chez un sujet ayant l'anemie
EP3431597A4 (en) IMMUNOCOMPETENT CELLS AND EXPRESSION VECTOR WITH EXPRESSION OF REGULATORY FACTORS OF IMMUNE FUNCTION
EP3381473A4 (en) PHARMACEUTICAL COMPOSITION FOR REDUCING LOCALIZED FAT AND USE OF THE PHARMACEUTICAL COMPOSITION
IL260684B (en) Treatment for modulating gut microbiota
MA71468A (fr) Compositions et méthodes pour diminuer l'expression de tau
EP3364958A4 (en) MODULATORS OF SESTRINE-GATOR2 INTERACTION AND USES THEREOF
EP3386432A4 (en) DETERMINATION OF THE PINE AND FACE MOVEMENT
MA43361A (fr) Composition pour le soin et la protection de cultures
EP2945475A4 (en) MELANOIDINES AND THEIR USE FOR IMPROVING THE PROPERTIES OF PLANTS
EP3395325A4 (en) LIQUID COSMETIC COMPOSITION
FR2999428B1 (fr) Chitine ou derives de chitine pour utilisation dans la prevention et/ou le traitement de parasitoses
EP3419656A4 (en) NEOANTIGEN COMPOSITIONS AND METHODS FOR USE THEREOF IN IMMUNOOTHERAPY
MA42148A (fr) Utilisation de prg4 pour améliorer l'acuité visuelle dynamique et les aberrations d'ordre supérieur
FR2999191B1 (fr) Souches probiotiques pour le traitement et/ou la prevention de la diarrhee
MA44968A (fr) Esters d'oxaborole et leurs utilisations
EP3365014A4 (en) METHOD AND COMPOSITIONS FOR TREATING SYSTEMIC MASTO CYTOSIS
MA52644A (fr) Compositions pharmaceutiques comprenant de l'acide dgla et leur utilisation
EP3520789A4 (en) NEW USE OF EXANOX